V CompBrief BY VELARION

Chief Financial Officer · Maze Therapeutics, Inc. (MAZE)

Misbah Tahir

FY2025 is the first fiscal year CompBrief holds for Misbah Tahir as a named executive officer of Maze Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$3,964,050

1st of 3 named executive officers at Maze Therapeutics by FY2025 total.

3 named officers on file for Maze Therapeutics, FY2025

See an example →

What this number hides

The filing gives the total. Maze Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Free

Get Misbah Tahir’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Misbah Tahir and every company like it: Velarion Intel, free for 3 days, no card →

Misbah Tahir compensation by year

Maze Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Maze Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$164,773
Bonus$50,000
Stock awards$0
Option awards$3,659,110
Non-equity incentive$86,667
Pension and deferred compensation$0
All other$3,500
Total$3,964,050

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Maze Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017463, and prior-year filings.

How this page was built: the Maze Therapeutics, Inc. filed document, accession 0001140361-26-017463. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option325,000—$15.32

Per the Outstanding Equity Awards at Fiscal Year-End table in Maze Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Maze Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Misbah Tahir · this pageChief Financial Officer$3,964,050
Jason ColomaChief Executive Officer$3,458,267
Harold BernsteinPresident, Research and Development and Chief Medical Officer$1,821,383

The full Maze Therapeutics compensation record

free company brief
Maze Therapeutics, Inc. (MAZE) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within Maze Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Maze Therapeutics's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosures
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Maze Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Misbah Tahir's compensation dossier